Introduction Current therapies for relapsing–remitting multiple sclerosis (RRMS) help reduce morbidity and delay disease progression. However, the available information on factors influencing decision-making regarding first-line treatment remain poorly understood. Methods Based on a review of […]
Introduction Relapses are a hallmark of multiple sclerosis, being a characteristic feature of relapsing-remitting multiple sclerosis (RRMS). The occurrence of a relapse constitutes a source of significant discomfort that impacts all domains of daily life […]
Introduction and objective Teriflunomide is an oral immunomodulatory agent approved for the treatment of relapsing–remitting multiple sclerosis (RRMS). We examined teriflunomide outcomes in patients with RRMS under clinical practice conditions in Spain. Material and methods […]
Introduction The objective of the present study was to evaluate the effectiveness and safety of teriflunomide in relapsing–remitting multiple sclerosis (RRMS) patients treated in a real-world setting. Methods This retrospective study was conducted at neurology […]
Background Red blood cell distribution width (RDW) reflects the variability of circulating red blood cells. The relationship between multiple sclerosis (MS) and RDW is not well studied. The main objective of this work was to […]